Summary
- Current Price
- As of today, EXEL price is $43.68, down -1.75% on
- Current Price All-Time High
- EXEL price is currently -13.50% below its historical high of $50.50 set on
- Market Cap
- EXEL current market cap is $11B, up +3.73% over the past 365 days
- PE Ratio
- EXEL current PE ratio is 15.69
- Revenue
- EXEL current annual revenue is $2.32B, up +6.98% year-over-year
- Next Earnings
- The next earnings release for EXEL is on
Profile
| Metric | Value |
|---|---|
| Full Name | Exelixis, Inc. |
| Ticker | NASDAQ: EXEL |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | exelixis.com |
| Employees | 1,147 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $43.68 | |
| Price, 1D Change | -1.75% | |
| Market Cap | $11B | |
| - | ||
| PE Ratio | 15.69 | |
| Beta | 0.79 | |
| Revenue | $2B | |
| Revenue, 1Y Change | +6.98% | |
| EPS | $2.78 | |
| EPS, 1Y Change | +57.73% |
Chart
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | EXL1V | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $2.78 | |
| EPS Estimate | N/A | $3.44 |
| EPS Est. Change | N/A | +23.87% |
| Revenue | $2.32B | |
| Revenue Estimate | N/A | $2.58B |
| Revenue Est. Change | N/A | +11.34% |
| Current Price | $43.68 | |
| Price Target | - | $49.00 |
| Price Tgt. Change | - | +12.18% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.94 | $1.76 | -9.43% | |
| $2.96 | $2.78 | -6.32% | |
| $3.44 | N/A | +23.87% | |
| $3.96 | N/A | +42.57% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.16B | $2.17B | +0.21% | |
| $2.32B | $2.32B | -0.09% | |
| $2.58B | N/A | +11.34% | |
| $2.93B | N/A | +26.08% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +12.32% | |
| Price, 3Y | +131.97% | |
| Market Cap, 1Y | +3.73% | |
| Market Cap, 3Y | +80.95% | |
| Revenue, 1Y | +6.98% | |
| Revenue, 3Y | +44.01% | |
| EPS, 1Y | +57.73% | |
| EPS, 3Y | +394.37% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $43.68 | |
| SMA 200 | $41.68 | |
| SMA 200 vs Price | -4.58% | |
| SMA 50 | $43.30 | |
| SMA 50 vs Price | -0.87% | |
| Beta | 0.79 | |
| ATR | $1.30 | |
| 14-Day RSI | 46.73 | |
| 10-Day Volatility | 38.30% | |
| 1-Year Volatility | 43.86% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $2.32B | |
| EPS | $2.78 | |
| Gross Profit | $2.24B | |
| Gross Margin | 96.39% | |
| Operating Profit | $892.70M | |
| Operating Margin | 38.48% | |
| Net Income | $782.57M | |
| Net Margin | 33.73% | |
| EBITDA | $921.76M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.09 | |
| 3.56 | ||
| 3.50 | ||
| - | ||
| 7 | ||
| 11.46 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 15.69 | |
| 4.78 | ||
| 5.13 | ||
| 11.11 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $2.16B | |
| $1.06B | ||
| $2.88B | ||
| $1.44B | ||
| $720.71M | ||
| $405.64M | ||
| Total Debt | $200.92M | |
| $27.88M | ||
| $29.62M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $1.54B | ||
| $1.34B | ||
| $83.70M | ||
| $0.00 | ||
| $29.06M | ||
| $0.00 | ||
| $158.64M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| $884.27M | ||
| $350.44M | ||
| -$969.59M | ||
| Capex | $8.43M | |
| $875.84M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Barclays | → | |
| RBC Capital | → | |
| HC Wainwright & Co. | → | |
| Wells Fargo | → | |
| Stifel | → | |
| RBC Capital | → | |
| Barclays | → | |
| HC Wainwright & Co. | → | |
| Morgan Stanley | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with EXEL
FAQ
What is the ticker symbol for Exelixis, Inc.?
The ticker symbol for Exelixis, Inc. is NASDAQ:EXEL
Does Exelixis, Inc. pay dividends?
No, Exelixis, Inc. does not pay dividends
What sector is Exelixis, Inc. in?
Exelixis, Inc. is in the Healthcare sector
What industry is Exelixis, Inc. in?
Exelixis, Inc. is in the Biotechnology industry
What country is Exelixis, Inc. based in?
Exelixis, Inc. is headquartered in United States
When did Exelixis, Inc. go public?
Exelixis, Inc. initial public offering (IPO) was on April 17, 2000
Is Exelixis, Inc. in the S&P 500?
No, Exelixis, Inc. is not included in the S&P 500 index
Is Exelixis, Inc. in the NASDAQ 100?
No, Exelixis, Inc. is not included in the NASDAQ 100 index
Is Exelixis, Inc. in the Dow Jones?
No, Exelixis, Inc. is not included in the Dow Jones index
When was Exelixis, Inc. last earnings report?
Exelixis, Inc.'s most recent earnings report was on February 10, 2026
When does Exelixis, Inc. report earnings?
The next expected earnings date for Exelixis, Inc. is May 5, 2026
Data Sources & References
- EXEL Official Website www.exelixis.com
- EXEL Profile on Yahoo Finance finance.yahoo.com/quote/EXEL
- EXEL Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/exel